A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma

Cancer Journal

Volumn 6, Issue 2, 2000, Pages 78-81

  Ajani, Jaffer A ^a   Kelsen, David P ^b   Haller, Daniel ^c   Hargraves, Kristin ^a   Healey, Diane ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Adenocarcinoma; Doxorubicin; Lewis(Y) antigen

Indexed keywords

BR 96 DOXORUBICIN CONJUGATE; DOXORUBICIN DERIVATIVE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CARCINOMA; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD15; ANTINEOPLASTIC AGENTS; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; SAFETY; STOMACH NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 0033913754     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pietersz GA, McKenzie IFC. Antibody conjugates for the treatment of cancer. Immunol Rev 1992;129:57-80.
2. Y-related cell surface antigen. Cancer Res 1990;50:2183-2190.
3. Trail PA, Willner D, Lasch SJ et al. Cure of xenograft human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261:212-215.
4. Saleh MN, LoBuglio AF, Trail PA. Monoclonal antibody-based immunoconjugate therapy of cancer: Studies with BR96-doxorubicin. In Grossbard ML ed. Monoclonal Antibody-Based Therapy of Cancer. New York: Mercel Dekker, 1998:397-415.
5. Fell HP, Yarnold S, Hellstrom I et al. Homologous recombination in hybridoma cells: heavy chain chimeric antibody produced via gene targeting. Proc Natl Acad Sci 1989;86:8507-8511.
6. Sugarman S, Murray JL, Saleh MN et al. A phase I study of BR96-doxorubicin (BR96-DOX) in patients with advanced carcinoma expressing the Lewis antigen [abstract]. Proc Am Soc Clin Oncol 1995;14:473.
7. Trail P, Onetto N, Lasch S et al. Tumor penetration and functional activity of BMS-182248 following administration in a phase I clinical trial [abstract]. Proc Am Assoc Cancer Res 1995;36:499.
8. Landis SH, Murray T, Bolden S et al. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
9. Comis S. Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1974;1:221-238.
10. Kelsen DP, Magill G, Cheng E et al. Phase II trial of etoposide (VP-16) in the treatment of upper gastrointestinal malignancies. Proc Am Soc Clin Oncol 1982;1:96.
11. Lacave A, Izarzugaza I, Aparicio L et al: Phase II clinical trial of cisdichlorodiommineplatinum in gastric cancer. Am J Clin Oncol 1983;6:35-38.
12. Ajani JA, Pazdur R, Dumas P et al. Phase II study of Taxol in patients with untreated metastatic gastric carcinoma. Cancer J Sci Am 1988;4:269-274.
13. Eingzig Al, Lipsitz S, Wiernik PH et al. Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract: The Eastern Cooperative Oncology Group (ECOG) Results. Invest New Drugs 1995;13:223-227.
14. Tamura F, Ohtsu A, Boku N et al. Three-hour infusion of paclitaxel for advanced gastric cancer. Proc ASCO 1997;16:307a.
15. Taguchi T. A late phase II study of docetaxel in patients with gastric cancer. Proc ASCO 1997;16:263a.
16. Sulkes A, Smyth J, Sessa C et al. Docetaxel in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994;70:380-383.
17. Einzig AI, Newberg D, Remick SC et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93.
18. Kambe M, Wakui A, Nakao I et al. A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers [abstract]. Proc ASCO 1993;12:198.
19. Takiuch H, Ajani JA. UFT (Uracil-Tegafur) in gastric carcinoma: a comprehensive review. J Clin Oncol 1998;16:2877-2885.
20. Horikoshi N, Mitachi Y, Sakata Y et al. Early phase II study of S-1, new oral fluoropyrimidine is very active in patients with advanced gastric cancer (early phase II study). Proc ACSO 1996;15:206.
21. Kurihara M, Koizumi W, Hasegawa K et al. Late phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with advanced gastric cancer [abstract]. Proc ASCO 1998;17:262a.
22. Cullinan SA, Moertel CG, Fleming TR et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin and mitomycin. JAMA 1985;253:2061-2067.
23. Wils JA, Klein HO, Wagener DJ et al: FAMTX (5-FU, Adriamycin and methotrexate): a step ahead in the treatment of advanced gastric cancer: a Trial of the European Organization for Research and Treatment of Cancer of the Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-831.
24. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. JCO 1997;15:161-167.
25. Wilke H, Wils J, Rougier P et al. Preliminary analysis of a randomized phase III trial of FAMTX vs. ELF vs. cisplatin/FU in advanced gastric cancer. Proc ASCO 1925;14:206.